Revyve Secures €24M Series B for Egg-Replacing Yeast Proteins

Revyve, a Dutch FoodTech scale-up, has secured €24 million in Series B funding. ABN AMRO Sustainable Impact Fund and Invest-NL co-led the round. This capital accelerates the global rollout of its functional yeast proteins.

The Wageningen-based company develops functional yeast proteins designed to replace eggs and additives in mainstream food categories. These ingredients mimic egg performance in bakery, sauces, and plant-based ingredients like alternative meat and dairy.

Revyve's total capital raised now exceeds €40 million.

Regional support came from Brabantse Ontwikkelings Maatschappij (BOM). Strategic investments were made by Lallemand Bio-Ingredients’ Swiss affiliate Danstar Ferment and Grey Silo Ventures. Existing investors Oost NL and Royal Cosun also participated.

Scaling Sustainable Egg Alternatives

Revyve's ingredients introduce authentic textures, helping replace animal proteins and "clean up" product labels. The solution addresses volatile egg prices, scrutiny of ultra-processed foods, and industry demands for reduced CO₂ footprints. Companies like Eat Just and Perfect Day also innovate in the egg alternative space.

Founded in 2021, Revyve emerged from Wageningen University & Research (WUR). The company commissioned its first production facility in Dinteloord, Netherlands, in 2024. This site already operates at capacity, proving industrial volume production.

The new investment expands output to over 1,600 tons per year. This ensures reliable supply for global accounts.